Want to see BMEA full AI Analyst Report?
BMEA Stock Chart & Stats
$2.21
$0.07(1.75%)
At close: 4:00 PM EST
$2.21
$0.07(1.75%)
Day’s Range― - ―
52-Week Range$0.87 - $2.99
Previous CloseN/A
Volume309.16K
Average Volume (3M)2.40M
Market Cap
$91.10M
Enterprise Value$66.80
Total Cash (Recent Filing)$44.69M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 03, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding72,299,440
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.20Price Target Upside225.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 2 T1D Clinical DataRobust, durable Phase 2 efficacy and a clean safety readout validate a differentiated, non‑immunosuppressive mechanism. That clinical de‑risking improves the probability of successful advancement, supports strategic partnership interest, and meaningfully strengthens the long‑term pipeline outlook.
Low Financial LeverageModest debt levels keep solvency risk low for a pre‑commercial biotech. Low leverage preserves flexibility to structure non‑debt financing or partnerships, limiting near‑term default risk and allowing management to prioritize development decisions without heavy interest or covenant constraints.
Improving Cash Burn And Net LossSustained reduction in operating cash outflows and narrower net losses indicates better cost control and program prioritization. If maintained, this trend extends runway, lowers near‑term financing frequency, and increases the chance of reaching developmental inflection points with less dilution.
Bears Say
No Commercial RevenueAbsence of product sales means the company depends on external financing, partnerships, or milestones to fund operations. This structural lack of recurring revenue increases funding sensitivity, constrains reinvestment capacity, and links survival to clinical and financing outcomes.
Eroding Capital BaseSharp decline in equity reflects cumulative losses consuming shareholder capital. A smaller capital base reduces financial buffer against setbacks, raises the likelihood of dilutive financings, and constrains flexibility to pursue parallel programs or extended trials without external support.
Persistent Negative Free Cash FlowConsistent negative free cash flow demonstrates that reported losses translate into real cash consumption. Even with improvement, sustained negative FCF forces repeat capital raises or deal‑making, which can dilute shareholders and limit the company’s ability to self‑fund longer or larger development programs.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $2.99 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $91.10M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Aug 03, 2026 which is in 15 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on May 06, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.231 by $0.061.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.22.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 72,299,440 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.231. Following the earnings report the stock price went up 1.875%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (225.79% Upside)
$7.20 (225.79% Upside)
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.77%
12-Months-Change
Fundamentals
Return on Equity
-196.72%
Trailing 12-Months
Asset Growth
-15.75%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
BMEA Stock 12 Month Forecast
Average Price Target
$7.20
▲(225.79% Upside)
Technical Analysis
Ownership Overview
8.66% Insiders
11.22% Mutual Funds
<0.01% Other Institutional Investors
75.99% Public Companies and
Individual Investors